Hologic, Inc. (NASDAQ:HOLX) Given Consensus Recommendation of “Hold” by Brokerages

Hologic, Inc. (NASDAQ:HOLX) has been given an average rating of “Hold” by the seventeen research firms that are covering the company, MarketBeat reports. Eleven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $84.62.

Several research analysts have issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research note on Monday, February 3rd. Citigroup dropped their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, Stephens reissued an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th.

Institutional Trading of Hologic

Institutional investors have recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after buying an additional 81,057 shares during the last quarter. Geode Capital Management LLC raised its stake in Hologic by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock worth $412,159,000 after acquiring an additional 144,838 shares during the last quarter. FMR LLC lifted its position in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the period. Victory Capital Management Inc. grew its stake in Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after purchasing an additional 24,358 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock valued at $322,272,000 after purchasing an additional 129,035 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Up 0.7 %

Shares of NASDAQ HOLX opened at $62.50 on Friday. Hologic has a 52-week low of $61.70 and a 52-week high of $84.67. The firm has a market capitalization of $14.02 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 2.14 and a beta of 0.97. The stock has a 50 day moving average price of $68.56 and a 200 day moving average price of $75.55. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts expect that Hologic will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.